Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Shareholder vote
confidence 98%
filed 2026-05-26
Item 5.07
This is a clear disclosure of shareholder vote results from State Street's Annual Meeting held on May 20, 2026, covering four proposals: election of thirteen directors, advisory vote on executive compensation, ratification of Ernst & Young LLP as auditor, and a shareholder proposal on board chair independence. The detailed voting tallies for each proposal are the core content of Item 5.07, and the results are material to investors as they reflect shareholder approval of board composition, compensation practices, and auditor selection.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-26
Item 5.07
This is a clear Item 5.07 disclosure of shareholder vote results from Thermo Fisher's May 20, 2026 Annual Meeting. The filing reports voting outcomes on three proposals: (1) election of 11 directors to the Board, (2) a non-binding advisory vote on named executive officer compensation that was not approved, and (3) ratification of PricewaterhouseCoopers LLP as independent auditor. The rejection of the say-on-pay proposal is material to investors as it signals shareholder dissatisfaction with executive compensation practices.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-05-26
Item 5.02
The disclosure centers on shareholder approval of amendments to the Non-Employee Director Stock Plan, which increased available shares from 450,000 to 865,114 and extended the plan expiration from 2029 to 2034. This is a compensatory arrangement amendment affecting director equity awards, fitting the exec_compensation category. The material nature reflects the substantial increase in equity pool available for director compensation.
View raw filing on EDGAR →
8-K
Covenant Breach
confidence 92%
filed 2026-05-26
Item 1.01
World Acceptance Corporation obtained a lender consent to temporarily modify its Fixed Charge Coverage Ratio covenant downward from 2.25x to 2.20x, 2.10x, and 2.15x for three consecutive quarters. This modification signals the Company was unable to maintain the original covenant level and required lender forbearance—a classic indicator of financial stress and covenant pressure. The temporary nature and subsequent reversion to 2.25x further suggest the Company anticipated near-term difficulty meeting its original obligation.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-26
Item 5.07
This Item 5.07 disclosure reports the results of ITT Inc.'s Annual Meeting of shareholders held on May 21, 2026, including voting outcomes for three matters: election of ten directors, ratification of Deloitte & Touche LLP as independent auditor, and advisory approval of 2025 named executive officer compensation. The filing presents detailed vote tallies (FOR, AGAINST, ABSTENTIONS, BROKER NON-VOTES) for each director and each proposal, which is the core content of a shareholder vote results disclosure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-26
Item 5.07
This is a clear disclosure of shareholder voting results from Ameris Bancorp's May 21, 2026 Annual Meeting of Shareholders, covering three proposals: election of 10 directors, ratification of KPMG LLP as independent auditor, and advisory approval of named executive officer compensation. The filing presents detailed vote tallies for each proposal, which is the hallmark of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-26
Item 5.07
Home Depot held its 2026 Annual Meeting of Shareholders with voting results on 12 proposals, including election of 12 directors, ratification of KPMG as auditor, advisory vote on executive compensation, charter amendments, and multiple shareholder proposals.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-26
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Gentex's 2026 Annual Meeting of Shareholders held on May 21, 2026. The filing presents voting outcomes for four proposals: election of nine directors, ratification of Ernst & Young LLP as auditors, advisory approval of named executive officer compensation, and approval of the 2026 Omnibus Incentive Plan. All proposals passed with substantial majorities, making this a material shareholder vote results disclosure.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-26
Item 8.01
PNC completed a public offering of $1.65 billion in senior notes ($1.35 billion fixed/floating rate and $300 million floating rate, both due October 2029). While debt issuances are material financing events affecting the registrant's capital structure and liquidity, this disclosure does not fit neatly into the standard 8-K taxonomy—it is neither a restatement, auditor change, going concern, impairment, delisting risk, bankruptcy, covenant breach, cybersecurity incident, nor dilutive equity issuance. The Item 8.01 classification and the nature of the transaction (completed debt offering under an existing registration statement) suggest this is a material financing event best captured as "other_material."
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-26
Item 5.07
First Keystone Corporation held its Annual Meeting of Shareholders on May 21, 2026, with voting results disclosed for three proposals: election of Class C Directors, ratification of Baker Tilly US, LLP as independent auditor, and an advisory vote on executive compensation.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-26
Item 8.01
Florida Power & Light sold $255.4 million in floating-rate debt securities on May 26, 2026. While this is a material financing event affecting the company's capital structure and future interest obligations, it does not fit cleanly into the standard 8-K taxonomy. The sale is not a dilutive equity issuance (dilutive_issuance applies to equity), not an M&A transaction (ma_activity), and not a covenant breach or going-concern disclosure. As a significant debt issuance by a utility, it is material to investors but lacks a dedicated event category.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-26
Item 5.07
TETRA Technologies held its Annual Meeting on May 22, 2026, with shareholders voting on four matters: election of eight directors, advisory vote on named executive officer compensation, ratification of Grant Thornton LLP as auditors, and approval of an amendment to the Tax Benefits Preservation Plan. Detailed vote tallies for each item are disclosed.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-26
Item 8.01
Following the Annual Meeting, John F. Glick was reappointed as Chair of the Board, and three Board committees were reconstituted. These governance actions affect board structure and oversight responsibilities.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-05-26
Item 5.02
Mark S. Peek resigned from his role as a director of Trimble Inc.'s Board effective immediately on May 26, 2026, and stepped down as Chair of the Audit Committee and from all committee memberships.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-05-26
Item 8.01
Thomas Sweet was appointed as Chair of the Audit Committee with explicit responsibility for overseeing remediation of material weaknesses in internal controls, a material governance matter affecting financial reporting oversight.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-05-26
Item 1.01
UGI Corporation's indirect subsidiaries AmeriGas Partners and AmeriGas Finance Corp. issued $500 million in senior unsecured notes on May 20, 2026, pursuant to a definitive indenture agreement, materially affecting the company's capital structure and financial obligations.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-05-26
Item 1.02
UGI Corporation executed a material debt restructuring through a tender offer accepting $468.5 million in 2027 Notes and full redemption of remaining notes on June 10, 2026, materially affecting the company's capital structure and debt obligations.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-26
Item 8.01
UGI announced early tender results for a $175 million cash tender offer of its 2028 Notes, with $224.8 million tendered (45.6% of outstanding notes) as of the early deadline and pro-rata acceptance at 77.9%, representing material debt management activity affecting the company's capital structure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-26
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Kadant Inc.'s 2026 annual meeting of stockholders held on May 20, 2026. The filing details voting outcomes on three proposals: election of two directors (Dr. John M. Albertine and Mr. Thomas C. Leonard), approval of a non-binding advisory resolution on executive compensation, and ratification of KPMG LLP as independent auditor. All three proposals passed with substantial majorities. This is material as shareholder votes on director elections and auditor ratification directly affect corporate governance and investor confidence.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-26
Item 5.07
This is a clear disclosure of shareholder voting results from Belden Inc.'s May 21, 2026 Annual Meeting of Stockholders, covering four proposals: election of ten directors, ratification of Ernst & Young as auditor, advisory vote on executive compensation, and approval of the amended 2021 Long Term Incentive Plan. The filing presents detailed vote tallies for each proposal, which is the quintessential content of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-26
Item 8.01
The Board of Directors approved a three-for-two stock split, which is a material capital structure change affecting all shareholders' ownership percentages and share count. While stock splits are routine corporate actions, they are material to investors as they affect share price, trading liquidity, and ownership calculations. This does not fit the dilutive_issuance category (which concerns new equity issuance) but represents a significant corporate action disclosed under Item 8.01.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-26
Item 5.07
This is a classic Item 5.07 disclosure reporting the final results of Labcorp's 2026 Annual Meeting of Shareholders. The filing details voting outcomes for three proposals: election of 11 directors to the Board, advisory approval of named executive officer compensation, and ratification of Deloitte & Touche LLP as independent auditor. The vote tallies (votes for, against, abstentions, and broker non-votes) are explicitly certified by the Inspector of Elections, which is the standard format for shareholder vote result disclosures.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-26
Item 1.01
Aspira entered into a Master Collaboration and License Agreement with Cleveland Clinic Foundation for biomedical research and development, with a $125,000 partnering fee over five years. While this is a material definitive agreement disclosed under Item 1.01, it does not constitute a traditional M&A transaction (no acquisition, merger, or change of control), and the collaboration arrangement with fixed fees and research focus does not fit the more specific event categories. The agreement is material to investors as it represents a significant strategic partnership and commitment of capital.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-05-26
Item 5.02
The disclosure centers on amended and restated compensatory arrangements for Christopher Martin, the Executive Chairman. The filing details modifications to his Executive Chairman Agreement (extending the term to May 21, 2028 and adding a Director Emeritus provision) and his Change in Control Agreement (modifying severance calculation and insurance coverage terms). These are material executive compensation arrangements that would affect investor assessment of the company's obligations and governance structure.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-05-26
Item 8.01
The filing discloses completion of an acquisition of First Aviation Services, a provider of defense and aviation MRO services. This is a material acquisition event that would affect investor assessment of the registrant's strategic direction and financial position. Although disclosed under Item 8.01 (Other Events), the substance is clearly M&A activity (completion of a material acquisition), which falls under the ma_activity classification.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-26
Item 5.07
Stoneridge held its 2026 Annual Meeting of Shareholders, with voting results on the election of nine directors, ratification of Ernst & Young LLP as auditors, advisory approval of named executive officer compensation, and approval of Amendment No. 1 to the 2025 Long-Term Incentive Plan increasing authorized shares by 2,650,000.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-26
Item 5.07
This is a classic Item 5.07 disclosure reporting the final results of TDS's Annual Meeting of Shareholders held on May 21, 2026. The filing presents voting tallies for four distinct matters: election of eight directors by Series A Common Share holders and four directors by Common Share holders, ratification of PricewaterhouseCoopers LLP as independent auditor, approval of certificate amendments for officer exculpation, and advisory approval of named executive officer compensation. All four proposals were approved. Shareholder vote results are material to investors as they confirm governance and audit oversight decisions.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-05-26
Item 8.01
TeraWulf entered into and closed a Membership Interest Purchase Agreement with Industrial Equity Partners for acquisition of the Muskie Data Campus, a strategically located hyperscale development site in Eastern Kentucky capable of supporting up to 1 gigawatt of data center capacity. The transaction closed effective May 22, 2026, and represents a material acquisition of real property and infrastructure assets that directly supports the Company's core business expansion strategy.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-05-26
Item 1.01
Encore Capital Group entered into a material definitive agreement on May 22, 2026, issuing $750 million in senior secured notes due 2032 with subsidiary guarantees and asset collateral, materially affecting the company's capital structure and financial obligations.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-26
Item 5.07
This Item 5.07 disclosure reports the results of Northern Oil & Gas's Annual Meeting of Stockholders held on May 21, 2026, including voting outcomes for three proposals: election of seven directors, ratification of Deloitte & Touche LLP as independent auditor, and advisory approval of named executive officer compensation. The filing presents vote tallies (For, Against, Abstain, Broker Non-Votes) for each proposal, which is the core content of shareholder vote results disclosures.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-05-26
Item 8.01
The filing discloses a common stock purchase agreement with White Lion Capital LLC for up to $15.0 million in equity financing, with actual purchases of 7,500 shares totaling $15,650 completed as of May 22, 2026. This represents a dilutive issuance of common stock under a committed purchase arrangement, which is material to investors assessing the registrant's capital structure and ownership dilution.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-26
Item 8.01
Editas disclosed positive preclinical data for EDIT-401 demonstrating robust reductions in LDL-C, Lp(a), and ApoB in non-human primates, along with plans to initiate a first-in-human clinical trial in 2026 and FDA pre-IND feedback. This announcement represents material progress on a lead pipeline candidate for a gene-editing biotech company where clinical advancement is a key value driver.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-05-26
Item 1.01
ARES Strategic Income Fund entered into an amendment and restatement of its senior secured credit facility with JPMorgan Chase Bank on May 21, 2026, materially increasing the aggregate commitment from $3.25 billion to $4.1 billion (with an accordion feature to $6.15 billion), extending maturity dates by approximately one year, and modifying key terms including interest rate mechanics and covenant restrictions.
View raw filing on EDGAR →
8-K
M&A activity
confidence 73%
filed 2026-05-26
Item 1.01
Ares Capital amended and restated its senior secured credit facility on May 21, 2026, increasing total commitments from $5.312 billion to $5.481 billion, extending maturity to May 21, 2031, and modifying covenant restrictions and interest rate terms. This material refinancing represents a significant modification to the Company's capital structure and financing arrangements.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-05-26
Item 1.01
The Company closed a $68 million Series B Revolving Equipment Notes Facility, generating $64.3 million in net cash proceeds. The facility is secured by aircraft collateral and includes cross-default provisions tied to Delta's credit agreement, representing a material financing transaction affecting the Company's liquidity and debt structure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-26
Item 5.07
This Item 5.07 disclosure reports the results of Passage Bio's 2026 Annual Meeting of Stockholders held on May 19, 2026, including voting outcomes on four proposals: election of two Class III directors (Athena Countouriotis, M.D. and Sandip Kapadia), ratification of KPMG LLP as independent auditor, advisory approval of named executive officer compensation, and advisory vote on compensation vote frequency. The filing presents vote tallies (For, Against, Abstaining, Broker Non-Votes) for each proposal, making this a classic shareholder_vote_results disclosure.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-26
Item 8.01
The FDA has granted Outlook's appeal of a Complete Response Letter for its BLA for LYTENAVA™, concluding that substantial evidence of effectiveness has been established and directing the company to work on final labeling for resubmission in June 2026. This is a material regulatory milestone for a biopharmaceutical company's lead product candidate, but it does not fit neatly into the standard taxonomy categories (not an earnings release, not a departure/appointment, not M&A, not a restatement or going-concern issue). The favorable FDA determination materially advances the product toward approval and would significantly affect investor assessment of the company's prospects.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-26
Item 5.07
This is a clear disclosure of shareholder voting results from Camping World's Annual Meeting of Stockholders held on May 21, 2026. The filing reports the outcomes of three proposals: election of three Class I directors (Mary J. George, K. Dillon Schickli, and Matthew D. Wagner), ratification of Deloitte & Touche LLP as independent auditor, and advisory approval of named executive officer compensation. All proposals passed with strong majorities, and the results are material to investors as they reflect governance decisions and shareholder approval of key corporate matters.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-05-26
Item 8.01
The filing discloses that Cypherpunk Technologies received a Nasdaq deficiency notice on March 4, 2026 for failing to maintain the minimum $1.00 bid price requirement for 30 consecutive business days, triggering delisting risk under Nasdaq Listing Rule 5550(a)(2). Although the company subsequently regained compliance by May 21, 2026, the disclosure of the initial deficiency notice and the cure period is a material delisting-risk event that would affect investor assessment of listing status and financial condition.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-26
Item 8.01
Editas suspended and terminated its prospectus supplement for an at-the-market (ATM) offering program with TD Cowen, effectively halting its ability to raise capital through this mechanism without filing a new prospectus. The company had previously raised $43.9 million through this program. While this is a material event affecting the company's financing flexibility, it does not fit neatly into the standard taxonomy—it is neither a dilutive issuance (which describes the sale itself) nor a delisting risk, but rather a suspension of an existing capital-raising program that would materially impact investor assessment of the company's liquidity and financing options.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-26
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Verastem's 2026 annual meeting of stockholders held on May 21, 2026. The filing presents voting outcomes for five proposals: election of Class II directors (Michael Bailey, Brian Stuglik, Karin Tollefson), approval of the Amended 2021 Equity Incentive Plan, approval of the Amended 2018 Employee Stock Purchase Plan, ratification of Ernst & Young LLP as auditor, and a non-binding advisory vote on named executive officer compensation. All proposals passed with substantial majorities, making this a material disclosure of shareholder voting results.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-26
Item 8.01
This disclosure reports interim clinical and biomarker data from a Phase 1b extension study of GT-02287 for Parkinson's disease, including safety, tolerability, and efficacy endpoints (GluSph reduction of 81%, stable MDS-UPDRS scores, and perceived clinical benefits). While this is a material clinical development update that would affect investor assessment of the drug candidate's progress, it does not fit neatly into the predefined taxonomy—it is neither an earnings release, M&A activity, executive change, nor a negative event like restatement or going concern. The disclosure is material because clinical trial progress is central to a biopharmaceutical company's value proposition.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-05-26
Item 5.02
Daniel J. Roller resigned from the Board of Directors effective immediately on May 21, 2026. The disclosure explicitly states this is a resignation under Item 5.02(b), which covers departures of directors and officers. The filing confirms no disagreement preceded the departure, but the loss of a board member is material to investors assessing governance and board composition.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-26
Item 5.07
This Item 5.07 discloses the final results of the 2026 Annual Meeting of Stockholders held on May 22, 2026, including voting outcomes for three proposals: election of six directors, advisory vote on named executive officer compensation, and ratification of Deloitte & Touche LLP as independent auditor. The detailed vote tallies (For, Against, Abstentions, Broker Non-Votes) for each proposal are the core disclosure, which is the defining characteristic of shareholder_vote_results.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-26
Item 5.07
This Item 5.07 disclosure reports the results of Gevo's 2026 Annual Meeting of Stockholders held on May 20, 2026, with detailed voting tallies for three proposals: election of three Class I directors (Barber, Bloom, Gruber), ratification of Deloitte & Touche LLP as independent auditor, and an advisory vote on named executive officer compensation. The filing directly matches the shareholder_vote_results event type and is material as it documents stockholder approval of board composition and auditor appointment.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-05-26
Item 5.02
Wendy Cassity, the Chief Legal Officer and Corporate Secretary of XPO, Inc., notified the company on May 20, 2026 of her intention to resign effective June 18, 2026. The departure of a named executive officer in a senior legal and governance role is material to investors' assessment of the company's leadership and operational continuity.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-05-26
The filing discloses Item 5.07 results from Global Net Lease's May 21, 2026 annual meeting of stockholders, including voting outcomes for three proposals: election of eight directors, ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of named executive officer compensation. The detailed vote tallies (For, Against, Withheld, Abstentions, Non-Votes) for each proposal are the core disclosure, making this a shareholder vote results event material to investors assessing board composition and governance.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-26
Item 5.07
This Item 5.07 disclosure reports the results of Miller Industries' Annual Meeting of Shareholders held on May 22, 2026, including voting outcomes on three matters: election of seven directors, non-binding advisory vote on named executive officer compensation, and ratification of Elliot Davis, LLC as independent auditor. The detailed vote tallies (for, against, withheld, abstain, non-votes) for each matter are the core content of a shareholder vote results disclosure, which is material to investors assessing board composition and governance.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-05-26
Item 1.01
Cogent Communications entered into a definitive Purchase and Sale Agreement to sell 10 data center facilities for $225 million to an I Squared Capital affiliate, representing a material disposition of assets that will significantly affect the company's asset base and cash position.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-26
Item 5.07
Bentley Systems held its 2026 Annual Meeting of Stockholders on May 21, 2026, with final voting results disclosed for three proposals: election of eight directors, advisory vote on named executive officer compensation, and ratification of KPMG LLP as independent auditor.
View raw filing on EDGAR →